Cyprotex PLC

("Cyprotex" or the "Company" or the "Group")

Publication of Annual Report & Accounts 2014

 & Notice of AGM - Update

Cyprotex PLC announces that its 2014 Annual Report and Accounts for the year ending 31 December 2014, together with the Notice of the Annual General Meeting and associated proxy form will today be posted to shareholders

The Annual Report and Accounts 2014 are available from the Company's website, www.cyprotex.com 

Further to the Final Results announcement of 15 April 2015, Cyprotex PLC's Annual General Meeting will now be held on Wednesday 17 June 2015 (and not on 25 June 2015) at 10.00 a.m. at the offices of N+1 Singer Advisory LLP, One Bartholomew Lane, London EC2N 2AX .

For further information:

Notes to Editors:

Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites in Macclesfield, near Manchester in the UK, Watertown, MA and Kalamazoo MI in the US. The Company was established in 1999 and works with more than 1,000 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries.  The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr^® toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe^® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com